|Day Low/High||0.57 / 0.59|
|52 Wk Low/High||0.44 / 2.03|
Novel first-in-class antibody enters clinic for second rare hypoglycemic indication
Data supports continued development of XOMA 129 as a novel targeted therapy for the treatment of hypoglycemic conditions
Trade-Ideas LLC identified XOMA (XOMA) as a weak on high relative volume candidate
Xoma stock is gaining on heavy trading volume early Thursday afternoon after the company reported its 2015 fourth quarter results after yesterday’s closing bell.
Xoma stock is jumping in after-hours trading on Wednesday after the company reported its 2015 fourth quarter results.
Company Advancing Its Endocrine Portfolio After Completing Divestiture of Non-Core Assets
Xoma stock is rising in early afternoon trading on Tuesday after Novo Nordisk bought its diabetes treatment for $295 million.
Trade-Ideas LLC identified XOMA (XOMA) as a strong on high relative volume candidate
XOMA's divests biodefense program to Nanotherapeutics, Inc.
The third quarter was brutal for biotech stocks. Here are the companies that fared the worst.
The Rosen Law Firm, a global investor rights firm, reminds purchasers of Xoma Corporation (NASDAQ:XOMA) securities during the period from November 6, 2014 through July 21, 2015 of the important September 22, 2015 lead...